FOR FURTHER INFORMATION PLEASE CONTACT:
Isotechnika Inc.
Dr. Robert T. Foster
Chairman and Chief Executive Officer
(403) 487-1600
(888) 487-9944
or
Isotechnika Inc.
Dr. Randall W. Yatscoff
President
(403) 487-1600
(888) 487-9944
--------------------------------------------------------------------------------
NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS
FOR: ISOTECHNIKA INC.
NOVEMBER 25, 1998
RE: Isotechnika Signs Distribution Agreements For
Diagnostic Kits
EDMONTON, ALBERTA--Isotechnika Inc. today announced that it has
signed agreements to distribute in China, Taiwan, Hong Kong, and
Brazil the company's breath test to detect ulcers.
The first of these agreements is with Baoshan Factory, a division
of the Shanghai Institute of Pharmaceuticals Industry to assemble
and distribute the breath test, Helikit, throughout China. The
exclusive agreement is for a guaranteed minimum of 830,000
diagnostic kits during a five-year period. Helikit already has
received government approval for use by the Chinese healthcare
system.
Another agreement, with Proto Corporation of Princeton, New
Jersey, guarantees 200,000 kits during a five-year period for
exclusive distribution in Taiwan and Hong Kong.
The third agreement is with Cansul Inc., of Brazil, for exclusive
distribution in the Brazilian market. The agreement guarantees a
minimum of 415,000 Helikits over five years.
"These exclusive agreements greatly extend our distribution of
Helikit," noted Joseph Koziak, Senior Vice President of
Isotechnika. "While the agreements provide for a guaranteed
minimum of nearly 1.5 million kits in total, we expect to exceed
this threshold. Helikit is the gold standard non-invasive test to
detect the active infection of H. pylori bacteria, and is less
costly than other methods of detection."
H. pylori causes almost all cases of gastric ulcers and many cases
of peptic ulcers. More than 20-40 percent of the North American
and European population, and more than 70 percent of the South
East Asian population is infected with the H. pylori bacteria.
Once diagnosed, the infection can be eradicated with antibiotic
therapy. Isotechnika's breath test already is sold in Korea and
the Philippines, and is sold in Canada under the name Pylori test.
Isotechnika Inc., of Edmonton, Alberta, is a life sciences company
that develops novel diagnostic products and therapeutic drugs.
The company's lead therapeutic products involve a patent-pending
process of atomic substitution to create new drugs to prevent
transplant rejection, such as Cyclosporine, and new compounds to
treat hypertension. A key advantage of this approach is reduced
R&D time. The company's R&D of new therapeutic drugs is supported
in part by an established revenue stream resulting from licensing
and strategic alliances for the development and sales of a number
of diagnostic products and services.
-30-
|
